Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis
Abstract
Elderly patients with rheumatoid arthritis, psoriasis and psoriatic arthritis encompass those with elderly-onset disease, over 60 years of age, but also those with earlier disease onset who entered old age. Considering the age-related changes of the immune system, possible frailty, susceptibility to infection and concomitant comorbidity that implies multiple medicines, the treatment of these diseases in elderly patients can be challenging. Interleukin inhibitors have been shown to be an efficient and safe treatment for these diseases. However, elderly patients with these diseases were often included in the pivotal clinical trials for interleukin inhibitors in numbers insufficient to determine whether they responded differently from younger subjects. The aim of this paper was to review the findings on the efficacy and safety of interleukin inhibitor treatment in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis. The findings suggest that, for all the interleukin inhibitors reviewed herein, used in elderly patients with rheumatoid arthritis, or with psoriasis and psoriatic arthritis, the efficacy was comparable to younger patients. Furthermore, the incidence of reported adverse events was similar in these two age groups. Severe adverse events, which were related to sarilumab treatment for rheumatoid arthritis and secukinumab treatment for psoriasis, were higher in elderly patients. The reviewed findings suggest that the interleukin inhibitors approved and currently in use in clinical practice for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis can be considered a safe and efficient option for these diseases in elderly patients.
References
United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019: Highlights. ST/ESA/SER.A/423. Available from:
https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf.
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;22;388(10055):2023-2038. Erratum in: Lancet. 2016 Oct 22;388(10055):1984.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377-390.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512-6.
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;27;6:15.
Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26 Suppl 2:3-11.
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278-285.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:545–68.
Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729-735.
Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72:736-40.
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2(Suppl 2):ii14-7.
Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 2003;48(4):917-26.
Olivieri I, Palazzi C, Peruz G, Padula A. Management issues with elderly-onset rheumatoid arthritis: an update. Drugs Aging. 2005;22(10):809-22.
Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226-9.
Kobak S, Bes C. An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(1):3-11.
Innala L, Berglin E, Möller B, Ljung L, Smedby T, Södergren A, et al. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2014;16(2):R94.
Huscher D, Sengler C, Gromnica-Ihle E, Bischoff S, Eidner T, Ochs W, et al. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol. 2013;31(2):256-62.
Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:906–910.
Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57:928–934.
Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology (Oxford). 2006;45:1555–1557.
Punzi L, Bertazzolo N, Pianon M, Rizzi E, Rossini P, Todesco S. Synovial fluid levels of proinflammatory interleukins and their inter-relationships in elderly vs younger onset rheumatoid arthritis. Aging (Milano). 1996;8(4):277-81.
Treharne GJ, Douglas KM, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007;5(4):175-90.
Kievit W, van Hulst L, van Riel P, Fraenkel L. Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: results from a choice-based conjoint analysis. Arthritis Care Res (Hoboken). 2010;62(6):842-7.
Theodorakopoulou E, Yiu ZZ, Bundy C, Chularojanamontri L, Gittins M, Jamieson LA, et al. Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. Br J Dermatol. 2016;175(5):1038-1044. doi: 10.1111/bjd.14886.
Queiro R, Tejón P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford). 2014;53(7):1178-85.
Allen MH, Ameen H, Veal C, Evans J, Ramrakha-Jones VS, Marsland AM, et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol. 2005;124(1):103-6.
Hébert HL, Bowes J, Smith RL, McHugh NJ, Barker JNWN, Griffiths CEM, et al. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. J Invest Dermatol. 2014;134(5):1459-1462.
Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol. 2012;51(1):53-8.
Phan C, Sigal ML, Estève E, Reguiai Z, Barthélémy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78-82.
Tsankov N, Irena A, Kasandjieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol. 2000;1:159–165.
Kim GK, Del Rosso JQ. Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol. 2010;3(1):32-8.
Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis. 1999;58:226–9.
Caso F, Tasso M, Chimenti MS, Navarini L, Perricone C, Girolimetto N, et al. Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management. Drugs Aging. 2019;36(10):909-925.
Magyari L, Varszegi D, Kovesdi E, Sarlos P, Farago B, Javorhazy A, et al. Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World J Orthop. 2014;5(4):516-36.
Zídek Z, Anzenbacher P, Kmonícková E. Current status and challenges of cytokine pharmacology. Br J Pharmacol. 2009;157(3):342-61.
Tsai YC, Tsai TF. Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness. Ther Adv Musculoskelet Dis. 2017;9(11):277-294.
Yang K, Oak ASW, Elewski BE. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review. Am J Clin Dermatol. 2021;22(2):173-192.
Orwig D, Rickles NM, Martin LG. Methodological issues in pharmacotherapy research in older adults. Am J Geriatr Pharmacother. 2011;9(3):173-89.
Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(10):604-13.
Hempenius L, Slaets JP, Boelens MA, van Asselt DZ, de Bock GH, Wiggers T, et al. Inclusion of frail elderly patients in clinical trials: solutions to the problems. J Geriatr Oncol. 2013;4(1):26-31.
Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014;21(3):209-14.
Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18(8):897-903.
Highlights of prescribing information - Cosentyx (secukinumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf.
Highlights of prescribing information - Siliq (brodalumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
Highlights of prescribing information - Taltz (ixekizumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf.
Highlights of prescribing information - Tremfya (guselkumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf.
Highlights of prescribing information - Ilumya (tildrakizumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf.
Highlights of prescribing information - Skyrizi (risankizumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf.
Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012;28(2):273-86.
De Spiegeleer B, Wynendaele E, Bracke N, Veryser L, Taevernier L, Degroote A, et al. Regulatory development of geriatric medicines: To GIP or not to GIP? Ageing Res Rev. 2016;27:23-36.
Meibohm B. The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs. In: Meibohm B, editor. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Weinheim: WILEY-VCH Verlag GmbH & Co; 2006; p. 1–13.
Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24(1):23-39.
ICH Topic E 7 Studies in Support of Special Populations: Geriatrics [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-7-studies-support-special-populations-geriatrics-step-5_en.pdf.
ICH topic E7 Studies in Support of Special Populations: Geriatrics Questions and Answers [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from:
EMA geriatric medicines strategy [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/documents/other/geriatric-medicines-strategy_en.pdf.
EMA geriatric medicines strategy [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from:
Points to consider on frailty: Evaluation instruments for baseline characterisation of clinical trial populations [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-points-consider-frailty-evaluation-instruments-baseline-characterisation-clinical-trial_en.pdf.
Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2017;19(1):10–19.
Müller L, Pawelec G. As we age: Does slippage of quality control in the immune system lead to collateral damage? Ageing Res Rev. 2015;23(Pt A):116-23.
Nikolich-Žugich J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol. 2014;193(6):2622-9.
Müller L, Di Benedetto S, Pawelec G. The immune system and its dysregulation with aging. Subcell Biochem. 2019;91:21-43.
Burkle A, Caselli G, Franceschi C, Mariani E, Sansoni P, Santoni A, et al. Pathophysiology of ageing, longevity and age related diseases. Immun Ageing 2007;4:4.
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590.
Milan-Mattos JC, Anibal FF, Perseguini NM, Minatel V, Rehder-Santos P, Castro CA, et al. Effects of natural aging and gender on pro-inflammatory markers. Braz J Med Biol Res. 2019;52(9):e8392.
Alvarez-Rodríguez L, López-Hoyos M, Muãoz-Cacho P, Martínez-Taboada VM. Aging is associated with circulating cytokine dysregulation. Cell Immunol. 2012;273:124–132.
Varadhan R, Yao W, Matteini A, Beamer BA, Xue QL, Yang H, et al. Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults. J Gerontol A Biol Sci Med Sci. 2014;69:165–73.
Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60.
Lee JS, Lee WW, Kim SH, Kang Y, Lee N, Shin MS, et al. Age-associated alteration in naive and memory Th17 cell response in humans. Clin Immunol. 2011;140(1):84-91.
Goetzl EJ, Huang MC, Kon J, Patel K, Schwartz JB, Fast K,et al. Gender specificity of altered human immune cytokine profiles in aging. FASEB J. 2010;24(9):3580-9.
Compté N, Zouaoui Boudjeltia K, Vanhaeverbeek M, De Breucker S, Tassignon J, Trelcat A, et al. Frailty in old age is associated with decreased interleukin-12/23 production in response to toll-like receptor ligation. PLoS One. 2013;8(6):e65325.
Fabbri LM, Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe 2006;3(1):40-49.
Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716–724.
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
Rempher KJ. Cardiovascular sequelae of tobacco smoking. Crit Care Nurs Clin North Am. 2006;18:13–20.
Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspect Clin Res. 2015;6(4):184-9.
Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res. 2016;111:592-599.
Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359-72.
Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos. 2007;35:1687–93.
Khatsenko OG, Gross SS, Rifkind AB, Vane J. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci. USA 1993;90:11147–51.
Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008;65(15):1413-8.
Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735-40.
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-8.
Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47(9):1104-18.
Highlights of prescribing information - Actemra (tocilizumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf.
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra#authorisation-details-section.
Highlights of prescribing information - Kevzara (sarilumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf.
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara#authorisation-details-section.
U.S. Food and Drug administration [Internet]. [cited 2021 Mar 31]. Available from:
https://www.fda.gov/media/107409/download.
Baskar S, Klein AL, Zeft A. The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review. Cardiol Res Pract. 2016;2016:7840724.
Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-52.
Highlights of prescribing information - Kineret (anakinra) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731-40.
Summary of product characteristics – RoActemra (tocilizumab) [Internet]. European Medicines Agency [cited 2021 Mar 31]. Available from: https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf.
Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017;77(17):1865-1879.
Pers YM, Schaub R, Constant E, Lambert J, Godfrin-Valnet M, Fortunet C, et al. Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(1):25-30.
van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
Specker C, Kaufmann J, Kellner H, Kästner P, Volberg C, Braunewell V et al. FRI0202 Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis. Ann Rheum Dis. 2016;75:504.
Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, et al. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2020 Jul 10. Epub ahead of print. PMID: 32662413.
June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303-9.
Rafique A, Martin J, Blome M, Huang A, Ouyang A, Papadopoulos N. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor alpha. Ann Rheum Dis. 2014;72:A797.
Fleischmann R, Genovese MC, van Adelsberg J, Mangan E, Iglesias-Rodriguez M, Dukovic D, et al. Pooled safety and efficacy of sarilumab in rheumatoid arthritis patients 65 years of age and older [abstract] Arthritis Rheumatol. 2016; 68 (suppl 10).
Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020;21(5):1690.
Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247-2259.
McKeage K. Ustekinumab: a review of its use in psoriatic arthritis. Drugs. 2014;74(9):1029-39.
Highlights of prescribing information - Stelara (ustekinumab) [Internet]. U.S. Food and Drug administration [cited 2021 Mar 31]. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761044s003lbl.pdf.
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/stelara#authorisation-details-section.
Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H, Nakagawa H. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41(11):974-80.
Megna M, Napolitano M, Balato N, Monfrecola G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564-6.
A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants with Psoriatic Arthritis (PsaBio) [Internet]. [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT02627768.
Gossec L, Theander E, Chakravarty S, Bergmans P, Lin I, Noël W, et al. Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10).
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx#authorisation-details-section
Megna M, Camela E, Cinelli E, Fabbrocini G. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45(7):848-852.
Körber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies. Drugs Aging. 2018;35(2):135-144.
McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, et al. (2020). Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. The Lancet Rheumatology, 2(4), e227–e235. doi:10.1016/s2665-9913(20)30036-9.
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/taltz#authorisation-details-section.
Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50.
Brembilla NC, Senra L, Boehncke WH. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front Immunol. 2018;9:1682.
Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17–26.
Megna M, Cinelli E, Balato A, Gallo L, Fabbrocini G. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol. 2020;34(3):e152-e153.
Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
European Medicines Agency [Internet]. [cited 2021 Mar 31]. Available from:
https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum#authorisation-details-section.
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2) [Internet]. [cited 2021 Mar 31]. Available from:
https://clinicaltrials.gov/ct2/show/NCT01708603?term=brodalumab%2C+AMAGINE-2&draw=2.
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3) [Internet]. [cited 2021 Mar 31]. Available from:
https://clinicaltrials.gov/ct2/show/NCT01708629?term=brodalumab%2C+AMAGINE-3&draw=2&rank=1.
Lebwohl M, Menter A, Yamauchi P, Wu JJ, Lin T. Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies. J Am Acad Dermatol. 2019;81:4:AB176.
Bakirtzi K, Sotiriou E, Papadimitriou I, Sideris N, Vakirlis E, Lallas A, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. J Dermatolog Treat. 2020:1-4. doi: 10.1080/09546634.2020.1809623. Epub ahead of print. PMID: 32783678.
Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676-1684.
